New drug MB0151 targets Hard-to-Treat cancers in early trial
NCT ID NCT06840821
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called MB0151 in adults with advanced solid tumors, including certain lung, breast, and neuroendocrine cancers. The goal is to check the drug's safety and see if it can shrink or control tumors. About 156 participants will receive the drug intravenously every two weeks, starting with low doses and increasing gradually.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cancer Hospital Affiliated to Shandong First Medical University
RECRUITINGJinan, Shandong, 250117, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can your own immune cells beat advanced cancer?
- Tumor DNA mapping may unlock personalized cancer therapies
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a High-Fiber diet shield the gut during breast cancer therapy?
- Can donor immune cells boost lung cancer remission?
- Could adding chest radiation extend life in advanced lung cancer?